Imv Inc (TSE:IMV) – Oppenheimer issued their FY2019 earnings per share estimates for IMV in a note issued to investors on Monday, November 25th. Oppenheimer analyst J. Olson anticipates that the company will post earnings per share of ($0.53) for the year. Oppenheimer currently has a “Outperform” rating and a $9.00 target price on the stock. Oppenheimer also issued estimates for IMV’s Q4 2019 earnings at ($0.13) EPS, FY2020 earnings at ($0.51) EPS, FY2021 earnings at ($0.46) EPS, FY2022 earnings at ($0.44) EPS and FY2023 earnings at ($0.25) EPS.
IMV (TSE:IMV) last announced its quarterly earnings data on Friday, November 8th. The company reported C($0.16) earnings per share for the quarter, missing the consensus estimate of C($0.12) by C($0.04). The business had revenue of C$0.16 million during the quarter, compared to analyst estimates of C$0.06 million.
Shares of TSE IMV opened at C$3.62 on Thursday. The stock has a fifty day simple moving average of C$3.44 and a two-hundred day simple moving average of C$4.00. IMV has a 1-year low of C$2.77 and a 1-year high of C$8.49. The firm has a market cap of $159.99 million and a price-to-earnings ratio of -6.57. The company has a current ratio of 4.47, a quick ratio of 3.87 and a debt-to-equity ratio of 66.56.
IMV Inc, a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system.
Recommended Story: Systematic Risk and Investors